Skip to main content

Table 4 Clinical trials using semaphorins/semaphorin receptors as targets for the therapy of cancer

From: SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia Identifier Recruitment status Aim of the trial Cancer histotype
NCT01313065 Phase 1 Completed Safety, tolerability, pharmacokinetics and pharmacodynamics of anti-Semaphorin 4D neutralizing monoclonal antibody, VX15/2503 (Pepinemab) Advanced solid tumors (Patnaik A et al Clin Cancer Res 2016)
NCT03268057 Completed Safety and tolerability of VX15/2503 in combination with avelumab Advanced non-small cell lung cancer
Phase 1, Phase 2
NCT03690986 Recruiting Efficacy of VX15/2503 in combination with ipilimumab or nivolumab Stage I-IVA head and neck squamous cell cancer
Phase 1
NCT03373188 Recruiting Efficacy of VX15/2503 with or without ipilimumab or nivolumab Resectable stage I-III pancreatic and stage IV colorectal cancer
Phase 1
NCT03769155 Recruiting Efficacy of VX15/2503 with or without ipilimumab and/or nivolumab Resectable Stage IIIB-D Melanoma
Phase 1
NCT03425461 Active, not recruiting Efficacy of VX15/2503 with nivolumab or ipilimumab Stage III or IV Melanoma
Phase I
NCT00747734 Completed Dose-limiting toxicities of anti-Neuropilin1 neutralizing monoclonal antibody, MNRP1685A Locally advanced or metastatic solid tumors (Weekes CD et al Invest New Drugs 2014)
Phase 1
NCT00954642 Completed Efficacy of MNRP1685A in combination with bevacizumab with or without paclitaxel Locally advanced or metastatic solid tumors (Patnaik A et al CancerChemotherapyPharmacology 2014)
Phase 1